Evidence map›Paper›PMID 28945351›Full record

ArticleBiochemistry2017

Metabolically Derived Lysine Acylations and Neighboring Modifications Tune the Binding of the BET Bromodomains to Histone H4.

Michael D Olp, Nan Zhu, Brian C Smith

Abstract readComparative Study
In one paragraph

Article in Biochemistry, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
1.5field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 31 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Zinc-chelating BET bromodomain inhibitors equally target islet endocrine cell types.American journal of physiology. Regulatory, integrative and comparative physiology · 2024
    Article
  6. Article
  7. Review
  8. Review
  9. Article
  10. Article
  11. Inhibiting BRD4 to generate BETter T cell memory.The Journal of experimental medicine · 2021
    Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

Michael D OlpDepartment of Biochemistry, Medical College of Wisconsin , Milwaukee, Wisconsin 53226, United States.
Nan ZhuStem Cell Biology and Hematopoiesis Program, Blood Research Institute, Blood Center of Wisconsin , Milwaukee, Wisconsin 53226, United States.
Brian C SmithDepartment of Biochemistry, Medical College of Wisconsin , Milwaukee, Wisconsin 53226, United States.ORCID 0000-0001-6330-2768
Medical College of Wisconsin · USVersiti Blood Center of Wisconsin · US

Funding

Medical Scientist Training ProgramT32GM080202 · NIGMS · MEDICAL COLLEGE OF WISCONSIN · PI BARBIERI, JOSEPH T, SALZMAN, NITA H · 2010 to 2024
$5.7M
The role of Jmjd1c in normal and leukemic hematopoiesisR00CA168996 · NCI · VERSITI WISCONSIN, INC. · PI ZHU, NAN · 2015 to 2017
$732k
American Heart Association-American Stroke Association 15SDG25830057NCI NIH HHS R00 CA168996NIGMS NIH HHS T32 GM080202
6 · The paper itself

Abstract

Recent proteomic studies discovered histone lysines are modified by acylations beyond acetylation. These acylations derive from acyl-CoA metabolites, potentially linking metabolism to transcription. Bromodomains bind lysine acylation on histones and other nuclear proteins to influence transcription. However, the extent bromodomains bind non-acetyl acylations is largely unknown. Also unclear are the effects of neighboring post-translational modifications, especially within heavily modified histone tails. Using peptide arrays, binding assays, sucrose gradients, and computational methods, we quantified 10 distinct acylations for binding to the bromodomain and extraterminal domain (BET) family. Four of these acylations (hydroxyisobutyrylation, malonylation, glutarylation, and homocitrullination) had never been tested for bromodomain binding. We found N-terminal BET bromodomains bound acetylated and propionylated peptides, consistent with previous studies. Interestingly, all other acylations inhibited binding of the BET bromodomains to peptides and nucleosomes. To understand how context tunes bromodomain binding, effects of neighboring methylation, phosphorylation, and acylation within histone H4 tails were determined. Serine 1 phosphorylation inhibited binding of the BRD4 N-terminal bromodomain to polyacetylated H4 tails by >5-fold, whereas methylation had no effect. Furthermore, binding of BRDT and BRD4 N-terminal bromodomains to H4K5acetyl was enhanced 1.4-9.5-fold by any neighboring acylation of lysine 8, indicating a secondary H4K8acyl binding site that is more permissive of non-acetyl acylations than previously appreciated. In contrast, C-terminal BET bromodomains exhibited 9.9-13.5-fold weaker binding for polyacylated than for monoacylated H4 tails, indicating the C-terminal bromodomains do not cooperatively bind multiple acylations. These results suggest acyl-CoA levels tune or block recruitment of the BET bromodomains to histones, linking metabolism to bromodomain-mediated transcription.

Indexed as

Models, MolecularProtein Processing, Post-TranslationalAcylationAnimalsBromodomain Containing ProteinsCell Cycle ProteinsCell LineChickensHistonesLigandsLysineMethylationMolecular Docking SimulationNuclear ProteinsNucleosomesOligopeptidesBRD2 protein, humanBRD3 protein, humanBRD4 protein, humanBRDT protein, humanBromodomain Containing ProteinsCell Cycle ProteinsHistonesLigandsLysineNuclear ProteinsNucleosomesOligopeptidesPeptide FragmentsProtein Serine-Threonine KinasesRecombinant Fusion ProteinsRNA-Binding ProteinsTranscription Factors

Identifiers

PMID28945351
PMCPMC5970795
OpenAlexW2757526256

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.